Skip Navigation

European Journal of Heart Failure 2008 10(9):817-818; doi:10.1016/j.ejheart.2008.06.017
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hauptman, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hauptman, P. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2008 European Society of Cardiology

All clinical trials are not created equal: The dilemma of HEAAL

Paul J. Hauptman*

Division of Cardiology, Saint Louis University School of Medicine United States

Key Words: Randomised clinical trial • Losartan • Dose

Received June 3, 2008; Accepted June 26, 2008

The first 10% of the full text of this article appears below.

"All animals are created equal but some are more equal than others"—George Orwell, Animal Farm [1]

Many of the core advances in clinical therapeutics in heart failure have come about through randomised clinical trials (RCTs). Over the last twenty years, trials have increased in sophistication and the results of these trials have directly impacted patient care and outcomes. Landmark studies have the weight of history behind them: from CONSENSUS [2] and V-HeFT [3] to SOLVD [4] and COPERNICUS [5], these are but a few of the names . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?